Literature DB >> 33249890

High mortality following revision hip arthroplasty for periprosthetic femoral fracture.

Tanvir Khan1,2, Rob Middleton3, Abtin Alvand3,4, Andrew R J Manktelow2, Brigitte E Scammell1,2,5, Benjamin J Ollivere1,2,5.   

Abstract

AIMS: To determine mortality risk after first revision total hip arthroplasty (THA) for periprosthetic femoral fracture (PFF), and to compare this to mortality risk after primary and first revision THA for other common indications.
METHODS: The study cohort consisted of THAs recorded in the National Joint Registry between 2003 and 2015, linked to national mortality data. First revision THAs for PFF, infection, dislocation, and aseptic loosening were identified. We used a flexible parametric model to estimate the cumulative incidence function of death at 90 days, one year, and five years following first revision THA and primary THA, in the presence of further revision as a competing risk. Analysis covariates were age, sex, and American Society of Anesthesiologists (ASA) grade.
RESULTS: A total of 675,078 primary and 74,223 first revision THAs were included (of which 6,131 were performed for PFF). Following revision for PFF, mortality ranged from 9% at 90 days, 21% at one year, and 60% at five years in the highest risk group (males, ≥ 75 years, ASA ≥ 3) to 0.6%, 1.4%, and 5.5%, respectively, for the lowest risk group (females, < 75 years, ASA ≤ 2). Mortality was greater in all groups following first revision THA for PFF than for primary THA. Compared to mortality risk after first revision THA for infection, dislocation, or aseptic loosening, revision for PFF was associated with higher five-year mortality in all groups except males < 75 years with an ASA ≤ 2.
CONCLUSION: Mortality risk after revision THA for PFF is high, reaching 60% at five years in the highest risk patient group. In comparison to other common indications for revision, PFF demonstrated the highest overall risk of mortality at five years. These estimates can be used in the surgical decision-making process and when counselling patients and carers regarding surgical risk. Cite this article: Bone Joint J 2020;102-B(12):1670-1674.

Entities:  

Keywords:  Mortality; National Joint Registry; Periprosthetic femoral fracture; Revision arthroplasty

Mesh:

Year:  2020        PMID: 33249890     DOI: 10.1302/0301-620X.102B12.BJJ-2020-0367.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  6 in total

1.  Optimal configuration of a three-rod ortho-bridge system in the treatment of Vancouver type B1 periprosthetic femoral fractures: A finite element analysis.

Authors:  Md Ariful Haque; Marcos Roberto Tovani-Palone; Thomas Franchi; Long Zhang; Jing Qin; Luyun Liu; Yingjie Zhang; Ying Xiong; Tong Wu; Jiayu Xiao
Journal:  J Orthop       Date:  2022-02-26

2.  The Impact of Prior Fragility Fractures on Complications After Total Hip Arthroplasty: A Propensity Score-Matched Cohort Study.

Authors:  Austin J Ross; Bailey J Ross; Olivia C Lee; George N Guild; William F Sherman
Journal:  Arthroplast Today       Date:  2021-08-19

3.  The Outcomes of Cemented Femoral Revisions for Periprosthetic Femoral Fractures in the Elderly: Comparison with Cementless Stems.

Authors:  Pavel Sponer; Martin Korbel; Michal Grinac; Libor Prokes; Ales Bezrouk; Tomas Kucera
Journal:  Clin Interv Aging       Date:  2021-10-27       Impact factor: 4.458

4.  Beyond Hip Fractures: Other Fragility Fractures' Associated Mortality, Functional and Economic Importance: A 2-year-Follow-up.

Authors:  Andreas Wiedl; Stefan Förch; Alexander Otto; Leonard Lisitano; Kim Rau; Thilo Nachbaur; Edgar Mayr
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-11-30

5.  Managing periprosthetic fractures - a review of the hub and spoke model.

Authors:  Srikanth Mudiganty; Luke Hughes; Qaisar Choudry; Awais Bokhari
Journal:  SICOT J       Date:  2022-01-18

6.  Factors influencing results and complications in proximal periprosthetic femoral fractures: a retrospective study at 1- to 8-year follow-up.

Authors:  Chiara Concina; Marina Crucil; Franco Gherlinzoni
Journal:  Acta Biomed       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.